global
burden
hepat
b
viru
hbv
infect
term
morbid
mortal
immens
novel
treatment
induc
protect
immun
respons
urgent
need
effect
control
hbv
epidem
eventu
erad
chronic
hbv
infect
design
evalu
hbv
therapeut
vaccin
consist
novel
tolllik
receptor
agonist
alum
adjuv
recombin
hbsag
protein
use
rnaseq
elisa
report
assay
character
vitro
realtim
pcr
evalu
tissueretent
characterist
vivo
evalu
adjuv
potenti
administr
intraperiton
formul
alum
adjuv
hbsag
normal
hbv
mice
evalu
hbsagspecif
immun
respons
elisa
elispot
assay
result
act
agonist
induc
similar
gene
express
pattern
unmodifi
ligand
raw
cell
expos
howev
potent
unmodifi
ligand
vivo
studi
show
tissueretain
activ
stimul
local
cytokin
chemokin
express
day
could
induc
immun
respons
evidenc
increas
hbsagspecif
titer
tcell
respons
normal
mice
compar
mice
receiv
tradit
alumadjuv
hbv
vaccin
importantli
could
break
immun
toler
induc
persist
hbsagspecif
antibodi
tcell
respons
hbv
mous
model
conclus
might
candid
adjuv
prophylact
therapeut
hbv
vaccin
chronic
hepat
b
viru
hbv
infect
major
global
health
problem
affect
million
peopl
worldwid
infect
eventu
lead
hepatocellular
carcinoma
liver
failur
cirrhosi
caus
million
death
everi
year
treatment
chronic
hbv
typic
involv
lifelong
administr
approv
drug
eg
nucleotid
therapi
costli
requir
patient
complianc
longterm
interferon
therapi
induc
mani
advers
effect
therefor
interrupt
treatment
result
unavoid
viral
rebound
less
patient
achiev
function
cure
defin
antihb
seroconvers
thu
urgent
need
new
treatment
effect
control
hbv
epidem
eventu
erad
chronic
hbv
infect
hbv
dna
viru
convert
coval
close
circular
dna
cccdna
host
cell
nucleu
licens
antivir
target
hbv
revers
transcriptas
activ
fail
elimin
cccdna
hbv
cccdna
elimin
current
achiev
antivir
immun
respons
howev
hbvspecif
cell
scarc
function
impair
context
chronic
hbv
infect
like
due
high
amount
circul
viral
hbeag
hbsag
therapeut
vaccin
combin
antivir
might
restor
function
tcell
respons
achiev
antihepat
b
seroconvers
minim
risk
advers
effect
numer
therapeut
vaccin
strategi
develop
past
year
even
enter
clinic
trial
unfortun
clinic
trial
show
disappoint
result
sophist
approach
warrant
break
immun
toler
boost
function
hbvspecif
immun
respons
individu
chronic
infect
mani
differ
approach
investig
preclin
model
overcom
immun
toler
chronic
hbv
infect
one
option
optim
hbv
compon
vaccin
dna
peptid
vaccin
vectorbas
cellbas
vaccin
multiepitop
therapeut
vaccin
candid
suffici
cover
differ
hbv
genotyp
develop
anoth
approach
develop
adjuv
break
immun
toler
induc
function
hbvspecif
immun
respons
inde
adjuv
technolog
one
lead
approach
develop
novel
safe
effect
vaccin
tolllik
receptor
tlr
type
pattern
recognit
receptor
prr
wide
express
immun
cell
abil
tlr
trigger
innat
immun
system
boost
adapt
immun
well
establish
one
hbv
therapeut
vaccin
clinic
trial
consist
hbv
antigenantibodi
hbsaghbig
complex
alum
activ
immun
cell
induc
protect
hbvspecif
immun
respons
addit
agonist
cpg
use
adjuv
improv
immun
control
persist
hbv
infect
agonist
also
report
induc
innat
cytokin
respons
suppress
hbv
replic
shape
adapt
immun
respons
achiev
durabl
control
hbv
infect
uniqu
design
agonist
show
adjuv
potenti
sivinfect
rhesu
monkey
treat
therapeut
vaccin
prophylact
vaccin
staphylococcu
aureu
howev
agonist
small
molecul
fast
metabol
narrow
drug
effect
window
properti
lead
ineffici
inconsist
result
thu
far
aim
gener
prefer
agonist
could
use
adjuv
hbv
therapeut
vaccin
chemic
synthes
novel
agonist
studi
drug
character
vitro
vivo
evalu
potenti
use
adjuv
hbv
therapeut
vaccin
term
break
immun
toler
trigger
high
qualiti
hbsagspecif
immun
respons
normal
mice
hbv
mous
model
femal
balbc
mice
age
week
old
purchas
anim
center
guangdong
provinc
guangdong
china
hous
specif
pathogen
free
spf
anim
area
anim
experi
perform
accord
declar
helsinki
protocol
approv
shenzhen
univers
school
medicin
anim
studi
committe
aavhbv
viru
provid
beij
fiveplu
molecular
medicin
institut
beij
china
recombin
viru
carri
copi
hbv
genom
genotyp
serotyp
ayw
packag
aav
serotyp
capsid
chemic
purchas
commerci
vendor
use
without
purif
unless
note
anhydr
n
ndimethylmethanamid
dmf
distil
cah
nonaqu
reaction
carri
nitrogen
atmospher
ovendri
glasswar
thin
layer
chromatographi
perform
use
precoat
silica
plate
merck
alum
sheet
visual
uv
light
h
nmr
c
nmr
spectra
obtain
bruker
avanc
iii
mhz
nmr
spectromet
chemic
shift
report
part
per
million
ppm
rel
intern
standard
tm
ppm
mass
spectra
obtain
agil
tof
lcm
system
methyl
benzonitril
compound
prepar
follow
previous
report
method
raney
ni
mg
ammonium
hydroxid
ml
ad
solut
compound
g
mmol
ml
reaction
mixtur
subject
hydrogen
atm
h
reaction
complet
mixtur
filter
filtrat
concentr
reduc
pressur
afford
compound
g
white
solid
esim
posit
suspens
compound
mg
mmol
concentr
hydrochlor
acid
ml
place
roundbottom
flask
reaction
stir
room
temperatur
overnight
mixtur
adjust
ph
n
naoh
purifi
precipit
wash
water
obtain
white
solid
mg
esim
posit
ion
mode
calcul
c
mg
mmol
dmf
ml
ad
dropwis
reaction
mixtur
stir
room
temperatur
h
reaction
complet
reaction
content
dilut
water
ml
filter
wash
icecold
water
crude
materi
purifi
flash
chromatographi
meohch
cl
afford
compound
white
solid
mg
macrophag
cell
seed
plate
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
densiti
cell
per
well
compound
ad
cultur
final
concentr
h
incub
total
rna
isol
purifi
use
rna
purif
kit
omega
biotek
doravil
usa
rnaseq
perform
bgiseq
platform
analyz
bgi
bgi
shenzhen
china
hekblu
report
cell
purchas
invivogen
invivogen
san
diego
usa
cell
stabli
express
human
seap
report
detect
agonist
signal
activ
cell
maintain
select
dmem
growth
medium
ml
blasticidin
zeocin
invivogen
san
diego
usa
incub
differ
dose
cell
test
use
hekblu
detect
kit
accord
manufactur
instruct
agonist
use
posit
control
induct
activ
visual
assess
read
od
nm
human
monocyt
cell
line
cell
incub
h
concentr
rang
cell
viabil
detect
cell
count
beyotim
china
human
peripher
blood
mononuclear
cell
pbmc
isol
human
buffi
coat
obtain
healthi
volunt
describ
previous
pbmc
ml
incub
variou
compound
h
co
cultur
supernat
collect
level
cytokin
supernat
determin
elisa
bd
bioscienc
pharmingen
la
jolla
ca
minimum
cytokin
detect
level
pgml
bone
marrowderiv
macrophag
bmdm
bone
marrowderiv
dendrit
cell
bmdc
isol
mice
grown
previous
describ
cell
seed
plate
densiti
cell
per
well
compound
ad
cultur
final
concentr
rang
h
incub
cultur
supernat
collect
assay
elisa
induct
bd
bioscienc
pharmingen
la
jolla
usa
minimum
detect
level
pgml
metabol
stabil
test
compound
test
concentr
determin
freshli
isol
spraguedawley
rat
hepatocyt
cryopreserv
primari
human
hepatocyt
incub
perform
use
cellsml
final
incub
volum
ml
william
e
medium
constant
temperatur
incub
shaker
aliquot
taken
min
control
min
min
h
h
h
reaction
quench
acetonitril
contain
ngml
tolbutamid
vortexmix
balbc
mice
n
inject
gastrocnemiu
muscl
nmol
vehicl
dmso
salin
volum
day
inject
muscl
harvest
immedi
frozen
liquid
nitrogen
store
total
rna
isol
cell
tissu
use
trizol
reagent
invitrogen
carlsbad
usa
rna
sampl
purifi
use
qiagen
rneasi
protect
kit
qiagen
valencia
usa
revers
transcript
carri
total
rna
use
superscript
iii
invitrogen
carlsbad
usa
serum
hbv
dna
extract
ul
serum
measur
follow
manufactur
instruct
qiagen
hilden
germani
cdna
hbv
dna
sampl
run
duplic
quantifi
realtim
pcr
biorad
hercul
usa
use
follow
primer
set
hbv
forward
atc
agg
att
cct
agg
revers
gag
tga
ttg
gag
gtt
forward
ggc
tgt
att
ccc
ctc
cat
revers
cca
gtt
ggt
aac
aat
gcc
forward
gat
gtg
cca
aac
gtc
revers
cac
ctt
gga
agc
cct
forward
gcc
aga
tgc
agt
taa
revers
tct
tga
gct
tgg
tga
forward
aca
cca
tga
agc
tct
revers
ttg
gtg
ctg
aga
acc
forward
aat
tcg
agt
gac
aag
revers
atc
cat
gcc
gtt
ggc
use
intern
control
sampl
load
normal
data
analyz
use
compar
ct
method
ct
cycl
number
fluoresc
first
exce
threshold
valu
cell
line
obtain
subtract
ct
valu
ct
valu
sampl
one
differ
ct
valu
repres
differ
level
mrna
mrna
level
express
percentag
respect
control
mice
inject
indic
amount
recombin
viru
dilut
phosphatebuff
salin
via
tail
vein
mice
bled
retroorbit
differ
time
point
monitor
hbv
surfac
antigen
hbsag
hb
antibodi
hbsab
hbv
genom
dna
level
serum
hbsag
hbsab
level
measur
use
architect
detect
kit
abbott
chicago
usa
follow
manufactur
instruct
purifi
hbsag
antigen
alum
adjuv
suppli
kangtai
biolog
product
co
ltd
shenzhen
chn
vivo
adjuvant
studi
uninfect
balbc
aavhbvinfect
mice
immun
intraperiton
hbsag
mix
nmol
without
alum
adjuv
day
mice
immun
normal
salin
hbsag
mix
vehicl
serv
control
serum
obtain
differ
time
point
hbsagspecif
antibodi
detect
splenocyt
isol
detect
hbsagspecif
tcell
respons
elispot
antihbsag
igg
antibodi
level
measur
elisa
architect
detect
kit
antihbsag
measur
previous
describ
briefli
elisa
plate
contain
titrat
previous
quantit
serum
gener
standard
curv
titer
standard
calcul
highest
dilut
serum
gave
absorb
read
doubl
background
variou
sera
sampl
use
dilut
result
express
unit
per
ml
calcul
base
unit
ml
standard
serum
mean
sd
five
anim
group
present
elispot
assay
cellswel
splenocyt
ad
duplic
plate
coat
antimous
bd
bioscienc
pharmingen
la
jolla
usa
hbsag
protein
ad
per
well
incub
h
number
spotform
cell
determin
use
axioplan
imag
system
zeiss
jena
germani
mous
antibodi
ab
cell
respect
isotyp
control
purchas
bio
x
cell
bio
x
cell
west
lebanon
usa
ab
inject
day
vaccin
administr
repeat
everi
day
maintain
cell
deplet
cell
deplet
confirm
flow
cytometri
peripher
blood
sampl
day
ab
inject
hbsag
mix
nmol
alum
adjuv
use
immun
day
hbsag
mix
alum
adjuv
alon
use
control
mice
sacrif
day
immun
splenocyt
isol
detect
hbsagspecif
tcell
respons
elispot
describ
data
express
mean
sd
statist
analysi
perform
graphpad
prism
softwar
data
analyz
oneway
anova
unpair
twotail
test
differ
consid
synthet
rout
compound
outlin
fig
began
methyl
benzonitril
compound
agonist
intermedi
previous
describ
lab
compound
obtain
via
reduct
group
intermedi
demethyl
compound
concentr
hydrochlor
acid
provid
analogu
synthes
coupl
agonist
intermedi
ethacryn
acid
ea
activ
hbtu
pharmacophor
ea
electrophil
keton
moieti
kept
evalu
activ
treat
raw
macrophag
overexpress
h
perform
rnaseq
identifi
chang
gene
express
respons
treatment
found
upregul
gene
downregul
gene
absolut
foldchang
raw
cell
treat
raw
cell
treat
fig
addit
file
tabl
compar
tlr
signal
stimul
upon
treatment
analyz
known
gene
involv
tlr
signal
identifi
pathcard
http
pathc
ardsgenec
ardsorg
rnaseq
dataset
found
similar
tlr
gene
express
pattern
treatment
raw
cell
six
gene
differenti
express
absolut
foldchang
six
gene
fig
addit
file
tabl
previous
report
interferon
stimul
gene
isg
analysi
show
isg
involv
tlr
signal
downregul
compar
addit
file
fig
addit
file
tabl
result
suggest
similar
biolog
function
unmodifi
term
stimul
tlr
signal
gene
differenti
effect
induc
isg
raw
cell
signal
activ
lead
activ
signal
manner
clarifi
specif
perform
report
assay
use
hekblu
report
cell
line
found
induc
potent
seap
reaction
hekblu
report
cell
activ
observ
induc
seap
reaction
hekblu
report
cell
suggest
specif
agonist
potent
fig
b
next
assess
immunolog
effect
pbmc
treat
pbmc
healthi
donor
differ
concentr
h
determin
level
supernat
found
show
differenti
capac
induc
express
specif
observ
higher
level
express
induc
respons
nm
treatment
compar
treatment
fig
higher
level
express
induc
respons
treatment
compar
treatment
human
pbmc
addit
file
fig
data
consist
rnaseq
analysi
show
treatment
induc
similar
gene
express
profil
gene
involv
tlr
signal
show
differ
activ
induc
isg
also
isol
bmdm
bmdc
mice
cultur
stimul
cell
differ
concentr
three
agonist
induc
express
dosedepend
manner
bmdm
bmdc
potent
agonist
ec
nm
ec
fig
evalu
activ
rnasequenc
cell
deg
treatment
raw
cell
treat
h
total
rna
extract
purifi
rnaseq
deg
among
mock
group
count
b
gene
express
pattern
base
gene
involv
tlr
signal
pathway
treatment
gene
tlr
signal
extract
pathcard
http
pathc
ardsgenec
ardsorg
gene
express
analyz
mock
treatment
group
deg
differenti
express
gene
nm
ec
nm
fig
addit
file
fig
accumul
evid
suggest
tissu
retent
indispens
characterist
agonist
function
vaccin
adjuv
test
activ
vivo
inject
nmol
normal
salin
gastrocnemiu
muscl
intramuscular
im
balbc
mice
perform
realtim
pcr
muscl
detect
local
cytokin
chemokin
express
day
found
could
induc
significantli
increas
express
day
im
inject
compar
group
fig
f
addit
file
fig
fig
agonist
induc
local
cytokin
chemokin
express
b
incub
cell
express
either
human
concentr
rang
hekblu
report
system
base
cell
stabli
transfect
seap
report
seap
activ
use
quantifi
activ
c
human
pbmc
ml
incub
concentr
rang
h
level
cultur
supernat
determin
elisa
bmdm
ml
deriv
mice
incub
concentr
rang
h
level
supernat
measur
elisa
e
f
balbc
mice
n
inject
nmol
vehicl
dmso
salin
volum
gastrocnemiu
muscl
day
inject
muscl
harvest
rna
isol
muscl
express
level
site
inject
determin
realtimepcr
student
test
use
data
analysi
data
repres
mean
sd
triplic
repres
three
independ
experi
p
bmdm
bone
marrow
deriv
macrophag
page
hu
et
al
j
transl
med
result
confirm
agonist
induc
local
cytokin
chemokin
express
agonist
effici
adjuv
induc
antigenspecif
respons
synergist
effect
report
administr
alum
adjuv
thu
use
adjuv
hbv
vaccin
administ
intraperiton
formul
alum
adjuv
recombin
hbsag
protein
normal
balbc
mice
day
agonist
use
control
evalu
hbsagspecif
humor
cellular
immun
respons
day
found
could
induc
high
titer
hbsagspecif
serum
effect
absent
tradit
alumadjuv
hbv
vaccin
observ
increas
hbsagspecif
titer
plu
alum
group
compar
group
fig
b
term
cellular
immun
respons
could
induc
high
qualiti
hbsagspecif
tcell
respons
evidenc
product
spot
form
cell
sfc
compar
group
increas
hbsagspecif
tcell
respons
observ
plu
alum
combin
group
compar
group
fig
effect
induc
hbsagspecif
tcell
respons
use
adjuv
hbv
vaccin
addit
nt
observ
signific
cytotox
cell
sideeffect
use
adjuv
vivo
evidenc
spleen
bodi
ratio
addit
file
fig
experi
best
perform
formul
seem
consist
nmol
hbsag
alum
adjuv
potenti
hbv
therapeut
vaccin
analysi
report
show
cpgodn
induc
cytotox
lymphocyt
activ
via
thelper
cellindepend
mechan
test
whether
effect
hbsagspecif
tcell
respons
regul
thelper
cellindepend
mechan
perform
cell
deplet
experi
antibodi
treatment
found
tcell
deplet
abrog
hbsagspecif
tcell
respons
hbv
therapeut
vaccin
cell
deplet
show
signific
effect
fig
f
result
impli
use
adjuv
induc
high
qualiti
hbsagspecif
immun
respons
celldepend
manner
chronic
hbv
infect
hbv
induc
immun
toler
part
secret
extrem
high
level
hbsag
hbeag
effect
like
skew
tcell
function
therapeut
vaccin
therefor
overcom
immun
toler
induc
protect
immun
respons
hbv
clearanc
test
effici
newli
design
hbv
therapeut
vaccin
consist
adjuv
alum
adjuv
recombin
hbsag
protein
break
immun
toler
hbv
mous
model
hbv
mous
model
gener
use
recombin
aav
carri
hbv
genom
aavhbv
previous
report
appropri
model
develop
novel
therapi
chronic
hbv
infect
two
month
tail
vein
inject
aavhbv
viru
administ
hbv
therapeut
vaccin
intraperiton
day
detect
hbsag
hbsab
hbv
genom
dna
serum
differ
time
point
sacrif
mice
evalu
hbsagspecif
tcell
respons
day
fig
hbv
therapeut
vaccin
could
induc
increas
persist
hbsab
respons
compar
tradit
hbv
vaccin
day
day
fig
signific
increas
hbsagspecif
tcell
respons
notabl
mice
receiv
hbv
therapeut
vaccin
achiev
hbsagspecif
tcellposit
respons
fig
also
note
signific
downregul
hbv
dna
copi
hbsag
titer
mice
receiv
hbv
therapeut
vaccin
compar
receiv
normal
salin
signific
differ
mice
receiv
hbv
therapeut
vaccin
tradit
vaccin
addit
file
fig
b
data
immun
intraperiton
hbsag
mix
nmol
day
hbsag
specif
measur
elisa
serum
obtain
day
third
immun
c
splenocyt
isol
day
third
immun
hbsagspecif
cell
detect
elispot
assay
cell
cultur
densiti
cellswel
hbsag
well
precoat
elispot
plate
h
e
f
group
balbc
mice
n
per
group
immun
intraperiton
hbsag
mix
nmol
alum
adjuv
day
cell
deplet
antibodi
treatment
splenocyt
isol
day
immun
elispot
assay
use
hbsagspecif
tcell
detect
cell
cultur
densiti
cellswel
hbsag
well
precoat
elispot
plate
h
student
test
use
data
analysi
data
repres
mean
sd
p
support
new
hbv
therapeut
vaccin
break
immun
toler
induc
high
qualiti
hbsagspecif
immun
respons
hbv
mous
model
test
metabol
stabil
vitro
hepatocyt
metabol
stabil
assay
use
elimin
halfliv
rat
human
primari
hepatocyt
h
h
intrins
clearanc
rate
liver
mlhkg
respect
addit
file
tabl
data
demonstr
fast
metabol
low
toxic
tlr
promis
target
design
develop
smallmolecul
immunomodul
serv
vaccin
adjuv
antiviralanticanc
agent
studi
aim
gener
prefer
agonist
could
use
adjuv
hbv
therapeut
vaccin
chemic
synthes
novel
agonist
conjug
report
agonist
ethacryn
acid
ea
function
group
keton
group
ea
kept
perform
rnaseq
evalu
activ
raw
macrophag
overexpress
tlr
retain
function
exhibit
unmodifi
term
stimul
similar
gene
involv
tlr
signal
note
howev
signific
differ
treatment
term
isg
induct
move
analys
report
cell
line
primari
immun
cell
vivo
model
character
found
agonist
potent
induc
express
compar
addit
exhibit
hbsagspecif
igg
level
serum
measur
elisa
indic
time
point
c
hbv
mice
sacrif
day
splenocyt
isol
hbsagspecif
cell
detect
elispot
assay
cell
cultur
densiti
cellswel
hbsag
precoat
elispot
plate
h
sfc
cell
shown
hbsagspecif
tcell
posit
rate
sfc
detect
elispot
cell
cultur
without
hbsag
stimul
use
neg
control
sfc
experiment
well
two
time
neg
control
well
regard
hbsagspecif
tcell
posit
sfc
spotform
cell
tissueretain
activ
could
stimul
local
cytokin
chemokin
express
day
evalu
adjuv
capac
administ
intraperiton
formul
alum
adjuv
recombin
hbsag
protein
could
induc
immun
respons
evidenc
increas
hbsagspecif
titer
tcell
respons
compar
tradit
hbv
vaccin
normal
mice
importantli
could
break
immun
toler
induc
persist
high
qualiti
hbsagspecif
antibodi
tcell
respons
hbvinfect
mice
data
thu
suggest
might
use
adjuv
prophylact
therapeut
hbv
vaccin
smallmolecul
characterist
tlr
agonist
render
easi
synthes
modifi
fast
metabol
narrow
drug
effect
window
properti
led
ineffici
inconsist
result
thu
far
therefor
sever
strategi
devis
optim
tlr
agonist
conjug
gag
protein
vaccin
develop
synergi
cpg
odn
augment
immun
respons
invent
novel
imidazoquinolin
adjuv
applic
studi
chemic
conjug
agonist
ea
ea
contain
keton
group
automat
bind
thiolcontain
protein
abund
resourc
thiolcontain
protein
cell
tissu
bodi
fluid
mean
keton
group
possess
new
drug
activ
system
acquir
exomethylen
group
found
enabl
automat
bind
sulphur
protein
gsh
propos
keton
group
might
underli
differ
pharmacodynam
pharmacokinet
characterist
compar
unmodifi
signal
activ
earli
newli
form
endosom
link
type
interferon
synthesi
wherea
signal
activ
latestag
endosom
induc
cytokin
manner
show
potent
activ
activ
compar
observ
significantli
differ
doedepend
activ
induc
gene
isg
clarifi
mechan
differ
activ
induc
gene
isg
think
distribut
endosom
vesicl
across
differ
stage
worth
explor
activ
lead
cytokin
product
mhc
costimulatori
molecul
upregul
dendrit
cell
dc
matur
thu
agonist
abl
drive
tcellmedi
bcellmedi
adapt
immun
respons
local
dc
cell
activ
critic
initi
adapt
immun
respons
howev
report
pharmacokinet
studi
human
imiquimod
solut
inject
subcutan
show
serum
level
detect
within
min
postdos
tmax
min
imiquimod
elimin
h
short
halflif
imiquimod
inject
site
like
suboptim
local
dc
activ
thu
novel
adjuv
alum
form
attach
agonist
alum
design
show
better
local
stimul
effect
adjuv
capac
compar
alum
alon
current
phase
clinic
develop
test
sever
diseas
model
context
staphylococcu
anthrax
meningococc
mening
infect
gener
coupl
molecul
local
retain
activ
evalu
potenti
adjuv
hbv
therapeut
vaccin
stimul
robust
hbsagdepend
respons
determin
induct
tcell
respons
normal
mice
also
found
synergist
effect
alum
combin
group
induc
increas
hbsagspecif
tcell
respons
compar
experiment
group
studi
show
could
break
immun
toler
induc
persist
high
qualiti
hbsagspecif
antibodi
tcell
respons
hbv
mous
model
compar
alum
small
molecul
easier
synthes
store
use
stabl
chemic
structur
howev
comparison
adjuv
capac
need
summari
gener
novel
agonist
known
promis
pharmacodynam
pharmacokinet
characterist
propos
might
use
adjuv
hbv
therapeut
vaccin
break
immun
toler
induc
high
qualiti
hbsagspecif
immun
respons
normal
hbv
mous
model
studi
need
confirm
potenti
adjuv
hbv
therapeut
vaccin
model
clinic
practic
believ
candid
applic
adjuv
prophylact
therapeut
hepat
b
vaccin
supplementari
inform
accompani
paper
http
doi
addit
file
tabl
complet
list
deg
raw
cell
treat
gene
absolut
foldchang
fc
